Literature DB >> 30668727

Mucosal Profiles of Immune Molecules Related to T Helper and Regulatory T Cells Predict Future Relapse in Patients With Quiescent Ulcerative Colitis.

Keita Fukaura1, Yoichiro Iboshi2, Haruei Ogino1, Eikichi Ihara1, Kazuhiko Nakamura3, Yuichiro Nishihara1, Kei Nishioka1, Takatoshi Chinen1, Tsutomu Iwasa1, Akira Aso1, Ayako Goto1, Kazuhiro Haraguchi3, Hirotada Akiho4, Naohiko Harada2, Yoshihiro Ogawa1.   

Abstract

BACKGROUND: T helper (Th)- and regulatory T (Treg) cell-related immune molecules are implicated in ulcerative colitis (UC). However, the association between their mucosal expression during remission and the subsequent clinical course of UC is unknown.
METHODS: The expression of cytokines and transcription factors related to Th1, Th2, Th17, and Treg in endoscopic mucosal biopsy specimens from 40 UC patients in clinical remission and 9 controls was measured by quantitative polymerase chain reaction. The relationship between their expression patterns, as stratified by Mayo Endoscopic Subscore (MES), and any future relapse was evaluated by univariate and multivariate analyses.
RESULTS: Six of 40 patients (baseline MES 0/1/2, 22/14/4) experienced a relapse during the study period (median, 37 months). At baseline, even in the MES0 patients, the interleukin (IL)-17A of the patients was significantly upregulated in comparison with controls (P = 0.0351). Future relapse was associated with a higher baseline expression of IL-17A, IL-17F, and IL-21 in MES0/1, and the upregulation of IL-17F and IL-21 remained statistically significant when limited to MES0 patients. Kaplan-Meier analysis revealed that as a single marker, a higher IL-21 level best grouped patients with an increased risk of relapse (P = 0.0042). Furthermore, a multivariate model that consisted of IL-21 and T-bet showed an even greater value (P = 0.0001).
CONCLUSIONS: The profiles of Th/Treg-related gene expression in the colonic mucosa are altered, even during clinical and endoscopic remission of UC, with a detectable Th17-predominant profile predicting future relapse. This association might represent latent immune dysregulation during disease quiescence and has the potential to be utilized to improve patient care.
© 2018 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  gene expression; prediction of relapse; quantitative PCR; ulcerative colitis

Mesh:

Year:  2019        PMID: 30668727     DOI: 10.1093/ibd/izy395

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  9 in total

1.  Maggot extracts promote regulatory T cell differentiation by upregulating Foxp3 in allergic rhinitis.

Authors:  Li Liu; Yu-Qin Deng; Wo-Er Jiao; Yue-Long Qiao; Ze-Zhang Tao; Yong Wang; Qing-Quan Hua; Shi-Ming Chen
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

Review 2.  Cross Talk between Gut Microbiota and Intestinal Mucosal Immunity in the Development of Ulcerative Colitis.

Authors:  Junfeng Zou; Chen Liu; Shu Jiang; Dawei Qian; Jinao Duan
Journal:  Infect Immun       Date:  2021-08-16       Impact factor: 3.441

3.  Increased mucosal IL-12 expression is associated with relapse of ulcerative colitis.

Authors:  Kazuhiko Uchiyama; Tomohisa Takagi; Katsura Mizushima; Mariko Kajiwara-Kubota; Saori Kashiwagi; Yuki Toyokawa; Makoto Tanaka; Yuma Hotta; Kazuhiro Kamada; Takeshi Ishikawa; Hideyuki Konishi; Mitsuo Kishimoto; Yuji Naito; Yoshito Itoh
Journal:  BMC Gastroenterol       Date:  2021-03-17       Impact factor: 3.067

4.  Expression of Th17/Treg Cells in Peripheral Blood and Related Cytokines of Patients with Ulcerative Colitis of Different Syndrome Types and Correlation with the Disease.

Authors:  Jianhua Yu; Shu Wang; Hongsheng Yuan; Tingyue Qiao; Miao Bao
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-23       Impact factor: 2.629

5.  Mucosa-associated gut microbiota reflects clinical course of ulcerative colitis.

Authors:  Yuichiro Nishihara; Haruei Ogino; Masaru Tanaka; Eikichi Ihara; Keita Fukaura; Kei Nishioka; Takatoshi Chinen; Yoshimasa Tanaka; Jiro Nakayama; Dongchon Kang; Yoshihiro Ogawa
Journal:  Sci Rep       Date:  2021-07-02       Impact factor: 4.379

6.  The Combination of Patient Profiling and Preclinical Studies in a Mouse Model Based on NOD/Scid IL2Rγ null Mice Reconstituted With Peripheral Blood Mononuclear Cells From Patients With Ulcerative Colitis May Lead to Stratification of Patients for Treatment With Adalimumab.

Authors:  Henrika Jodeleit; Janina Caesar; Christina Villarroel Aguilera; Sebastian Sterz; Lesca Holdt; Florian Beigel; Johannes Stallhofer; Simone Breiteneicher; Eckart Bartnik; Matthias Siebeck; Roswitha Gropp
Journal:  Inflamm Bowel Dis       Date:  2020-03-04       Impact factor: 5.325

7.  The Imbalance of Circulating Follicular Helper T Cells and Follicular Regulatory T Cells Is Associated With Disease Activity in Patients With Ulcerative Colitis.

Authors:  Yan Long; Changsheng Xia; Lijuan Xu; Caoyi Liu; Chunhong Fan; Huizhang Bao; Xiaotao Zhao; Chen Liu
Journal:  Front Immunol       Date:  2020-02-14       Impact factor: 7.561

8.  Qingchang Huashi granule ameliorates experimental colitis via restoring the dendritic cell-mediated Th17/Treg balance.

Authors:  Jia Jia; Kai Zheng; Hong Shen; Jiangyi Yu; Ping Zhu; Shihai Yan; Yi Xu; Lei Zhu; Yuelin Lu; Peiqing Gu; Wan Feng
Journal:  BMC Complement Med Ther       Date:  2020-09-23

9.  Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: A meta-analysis.

Authors:  Xuemei Jia; Ruitong Guo; Zhenbiao Hu; Jianxin Liu; Jianping Liu; Bolin Li; Qian Yang; Jianming He
Journal:  Medicine (Baltimore)       Date:  2020-10-30       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.